Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 57 citing articles:

The BET family in immunity and disease
Nian Wang, Runliu Wu, Daolin Tang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 212
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Pan Tang, Jifa Zhang, Jie Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2419-2435
Open Access | Times Cited: 109
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
Robert J. Watson, Paul Bamborough, Heather Barnett, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 9045-9069
Closed Access | Times Cited: 71
Bromodomain inhibitors and therapeutic applications
G. Bharath Kumar, Ming‐Ming Zhou
Current Opinion in Chemical Biology (2023) Vol. 75, pp. 102323-102323
Open Access | Times Cited: 30
Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning
Jian Wang, Wanchun Yang, Lu Zhao, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1857-1857
Open Access | Times Cited: 13
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia
Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1513-1532
Closed Access | Times Cited: 10
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Domain-selective targeting of BET proteins in cancer and immunological diseases
M. Petretich, Emmanuel H. Demont, Paola Grandi
Current Opinion in Chemical Biology (2020) Vol. 57, pp. 184-193
Open Access | Times Cited: 50
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Juncheng Chen, Pan Tang, Yuxi Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5184-5211
Closed Access | Times Cited: 36
Targeting bromodomain-containing proteins: research advances of drug discovery
Zhaoping Pan, Yuxi Zhao, Xiaoyun Wang, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 18
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors
Yi Zhang, Deqin Rong, Bingbing Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 7900-7925
Closed Access | Times Cited: 37
Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit
Francesco Rianjongdee, Stephen J. Atkinson, Chun‐wa Chung, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10806-10833
Closed Access | Times Cited: 36
Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections
Ram K. Modukuri, Zhifeng Yu, Zhi Tan, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 22
Open Access | Times Cited: 26
Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases
Zhijie Wang, Li Yin, Zhenghan Xiong, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10824-10848
Closed Access | Times Cited: 13
Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors
Yangfeng Li, Zhengnan Shen, Kiira Ratia, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2712-2731
Closed Access | Times Cited: 5
Biological properties of pyrroloquinoline and pyrroloisoquinoline derivatives
Petra Králová, Miroslav Soural
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116287-116287
Closed Access | Times Cited: 4
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 529-545
Closed Access | Times Cited: 4
Discovery of selective ROCK2 inhibitors with free radical scavenging ability for the treatment of gouty arthritis
Ruolin Cao, Chuqiao Song, Zhe Wang, et al.
Molecular Diversity (2025)
Closed Access
Multi-Water Bridges Enable Design of BET BD1-Selective Inhibitors for Pancreatic Cancer Therapy
Xuetao Chen, Wenjing Kang, Tingting Wu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Kaixuan Qibi granules attenuate myocardial fibrosis through BRD4 blockade regulated by the NF-κB/NLRP3 signaling pathway
Rui Huang, Gang Luo, Mengnan Liu, et al.
Journal of Traditional and Complementary Medicine (2025)
Open Access
Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors
Junhua Li, Qingqing Hu, Run Zhu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Targeting epigenetic reader domains by chemical biology
Alessandra Cipriano, Gianluca Sbardella, Alessio Ciulli
Current Opinion in Chemical Biology (2020) Vol. 57, pp. 82-94
Closed Access | Times Cited: 25
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen Aylott, Stephen J. Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 6, pp. 3249-3281
Closed Access | Times Cited: 23
Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
Qianqian Wang, Xiaomin Shao, Elaine Lai Han Leung, et al.
Pharmacological Research (2021) Vol. 172, pp. 105804-105804
Closed Access | Times Cited: 22
Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis
Yuqin Zhu, Yuxiang Ma, Weidong Zu, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 13, pp. 6748-6773
Closed Access | Times Cited: 22
Page 1 - Next Page

Scroll to top